{
    "id": 25104,
    "fullName": "ESR1 - CCDC170",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ESR1-CCDC170 results from the fusion of ESR1 and CCDC170, which leads to increased motility, colony formation, and transformation in cell culture and demonstrates increased tumor growth in mouse models (PMID: 25099679).",
            "references": [
                {
                    "id": 6426,
                    "pubMedId": 25099679,
                    "title": "Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25099679"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "ESR1 - CCDC170",
    "createDate": "08/03/2016",
    "updateDate": "12/07/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 80129,
                "geneSymbol": "CCDC170",
                "terms": [
                    "CCDC170",
                    "bA282P11.1",
                    "C6orf97"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15403,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell line xenograft models overexpressing ESR1-CCDC170 treated with Nolvadex (tamoxifen) demonstrated slower tumor regression and worse progression-free survival compared to Nolvadex (tamoxifen) treated control (Cancer Res 2016;76(4 Suppl):Abstract nr PD2-05).",
            "molecularProfile": {
                "id": 25870,
                "profileName": "ESR1 - CCDC170"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13141,
                    "pubMedId": null,
                    "title": "Abstract PD2-05: Evaluating the role of recurrent ESR1-CCDC170 in breast cancer endocrine resistance",
                    "url": "http://cancerres.aacrjournals.org/content/76/4_Supplement/PD2-05.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25870,
            "profileName": "ESR1 - CCDC170",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}